Compare GLAS & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLAS | KMDA |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.2M | 460.3M |
| IPO Year | 2021 | 2013 |
| Metric | GLAS | KMDA |
|---|---|---|
| Price | $4.08 | $7.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.00 | $13.50 |
| AVG Volume (30 Days) | ★ 1.4M | 108.6K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 5.20% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.49 | $9.50 |
| Revenue Next Year | $27.75 | $12.63 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.15 | $6.55 |
| 52 Week High | $12.70 | $9.35 |
| Indicator | GLAS | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 12.55 | 41.34 |
| Support Level | N/A | $6.94 |
| Resistance Level | $10.53 | $8.58 |
| Average True Range (ATR) | 0.52 | 0.20 |
| MACD | -0.18 | -0.11 |
| Stochastic Oscillator | 4.23 | 13.06 |
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.